Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
OncoCyte Corp is a biotechnology business based in the US. OncoCyte shares (OCX) are listed on the NASDAQ and all prices are listed in US Dollars. OncoCyte employs 110 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Active traders
| Latest market close | $0.89 |
|---|---|
| 52-week range | $0.84 - $6.25 |
| 50-day moving average | $1.09 |
| 200-day moving average | $1.99 |
| Wall St. target price | $3.15 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.77 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.889 from 2022-07-05
| 1 week (2022-06-30) | -1.19% |
|---|---|
| 1 month (2022-06-07) | -24.66% |
| 3 months (2022-04-06) | -36.50% |
| 6 months (2022-01-03) | N/A |
| 1 year (2021-07-07) | -84.13% |
|---|---|
| 2 years (2020-07-07) | -28.88% |
| 3 years (2019-07-05) | 2.13 |
| 5 years (2017-07-07) | 5.05 |
| Revenue TTM | $8 million |
|---|---|
| Gross profit TTM | $188,000 |
| Return on assets TTM | -22% |
| Return on equity TTM | -86.15% |
| Profit margin | 0% |
| Book value | $0.62 |
| Market capitalisation | $106.6 million |
TTM: trailing 12 months
We're not expecting OncoCyte to pay a dividend over the next 12 months.
Over the last 12 months, OncoCyte's shares have ranged in value from as little as $0.836 up to $6.25. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while OncoCyte's is 1.8752. This would suggest that OncoCyte's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California. .
Everything we know about the Citrine Global IPO, plus information on how to buy in.
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.